Forbes Medi-Tech sells pharma assets
This article was originally published in The Tan Sheet
Executive SummaryForbes Medi-Tech will sell its pharmaceutical assets and business unit in San Diego to Transition Therapeutics for $1 million in cash upfront. Transition could pay as much as $6 million more based on predetermined milestones. The sale will allow Forbes to focus on its nutraceutical business, Forbes President and CEO Charles Butt says in an Aug. 18 release
You may also be interested in...
For health-care providers and medtech manufacturers alike, the decade ahead will require a coming to terms with digital technologies and integrating new methods of payment. Quality of service delivery remains the market-entry criterion, but companies will have to adapt to evolving health-care models. The stakes are high. Will manufacturers be able to capitalize on the changes in a market that is more competitive and unpredictable than ever?